GGrantIndex
← Leaderboards

University Of Calgary

Calgary, AB

Compare ↔
$40,271,646
Total funding
38
Grants

Funding over time

peak $3.8M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$40,259,646 · 37
NSF$12,000 · 1

By mechanism

R01$29,908,528 · 20
U01$7,237,558 · 4
R21$2,077,240 · 9
U10$697,675 · 1
R34$222,699 · 1
R03$107,946 · 1

Investigators at University Of Calgary

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Peter K Stys$1,142,5381 gr

Emerging Leaders

6–10 yrs in

1Scott D Gray-Owen$4,863,8834 gr2Trevor F Moraes$1,450,6631 gr3Anthony Bernard Schryvers$1,450,6631 gr4Sabine Gilch$670,9501 gr5Nathan C. Peters$295,9841 gr6John Andrew Cobb$107,9461 gr

All-Time

Most funded here, all years

1Scott D Gray-Owen$4,863,8834 gr2Sui Rong Wayne Chen$4,622,4174 gr3Christopher Power$2,638,4323 gr4Peter D Vize$2,334,5322 gr5Roy A Gravel$1,586,9571 gr6Anthony Bernard Schryvers$1,450,6631 gr7Trevor F Moraes$1,450,6631 gr8Peter K Stys$1,142,5381 gr

Largest grants

Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. Coli Infection (HIKO STEC): A Multinational, Embedded, Cluster, Crossover, Randomized Trial$2,039,155
R01 · FY2023 · AI
Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. Coli Infection (HIKO STEC): A Multinational, Embedded, Cluster, Crossover, Randomized Trial$1,959,301
R01 · FY2024 · AI
Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. Coli Infection (HIKO STEC): A Multinational, Embedded, Cluster, Crossover, Randomized Trial$1,520,407
R01 · FY2021 · AI
Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. Coli Infection (HIKO STEC): A Multinational, Embedded, Cluster, Crossover, Randomized Trial$1,472,834
R01 · FY2022 · AI
Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. Coli Infection (HIKO STEC): A Multinational, Embedded, Cluster, Crossover, Randomized Trial$1,459,892
R01 · FY2025 · AI
Production of a Gonococcal Vaccine for Countering Antimicrobial Resistance$1,112,000
R01 · FY2019 · AI
Production of a Gonococcal Vaccine for Countering Antimicrobial Resistance$1,017,518
R01 · FY2024 · AI
Production of a Gonococcal Vaccine for Countering Antimicrobial Resistance$810,000
R01 · FY2020 · AI
Production of a Gonococcal Vaccine for Countering Antimicrobial Resistance$810,000
R01 · FY2021 · AI
Glanders Vaccine Developement$687,491
U01 · FY2010 · AI
Production of a Gonococcal Vaccine for Countering Antimicrobial Resistance$602,472
R01 · FY2023 · AI
Glanders Vaccine Developement$590,862
U01 · FY2009 · AI
"7/9" Predictors and Mechanisms of Conversion to Psychosis$493,867
U01 · FY2016 · MH
"7/9" Predictors and Mechanisms of Conversion to Psychosis$456,081
U01 · FY2014 · MH
"7/9" Predictors and Mechanisms of Conversion to Psychosis$454,827
U01 · FY2015 · MH
7/8 Predictors and Mechanisms of Conversion to Psychosis$451,428
U01 · FY2008 · MH
7/8 Predictors and Mechanisms of Conversion to Psychosis$448,413
U01 · FY2011 · MH
7/8 Predictors and Mechanisms of Conversion to Psychosis$437,618
U01 · FY2010 · MH
Xenbase: a Xenopus Model Organism Database$410,755
R01 · FY2005 · HD
Xenbase: a Xenopus Model Organism Database$401,118
R01 · FY2006 · HD